In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Orna Therapeutics (through its wholly owned subsidiary ReNAgade Therapeutics Inc.) announced a three-year strategic research collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq ...

Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price ...

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research ...

TG Therapeutics exceeded 2024 revenue guidance by 24%, signaling strong growth and market share capture with its Multiple Sclerosis treatment, Briumvi. 2025 revenue guidance of $540 million ...

(Image Credits: Pixabay) Immuneel Therapeutics on Monday launched Qartemi, a CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL). According to the company’s statement, it is ...

This page features the latest news about the Kyverna Therapeutics stock. Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms ...

A Quick Take On Odyssey Therapeutics, Inc. Odyssey Therapeutics, Inc. (ODTX) has filed to raise $100 million in an IPO of its ordinary shares, according to SEC S-1 registration information.

2/- to Re. 1/-. 13-Jun-22 10 2 Stock split from Rs. 10/- to Rs. 2/-. Darshan Orna Limited is an India-based integrated wholesaler of Jewelry and Ornaments. The Company is also into the trading ...

Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a session titled "Bi and Multispecific Biologics" and ...